🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎥It was great to hear from Ben Creelan, MD (Moffitt Cancer Center) and @AllisonBetofWarner (Stanford Cancer Institute) who discussed updates in #TILs in solid tumors including promising T-cell targets in #LungCancer as well as optimizing TILs in #Melanoma Watch the full discussion soon on

Report Nature Cancer from Ben Creelan, MD et al describes resistance to #TIL (tumor infiltrating lymphocyte) therapy including loss of subclonal neoantigens targeted by TILs, loss of antigen-specific immune clones, and HLA LOH. nature.com/articles/s4301…

Just published in Nature Cancer: New #LungCancer study highlights challenges and opportunities for TIL therapy Ben Creelan, MD Stand Up To Cancer Moffitt Cancer Center moffitt.org/newsroom/news-…

Fantastic paper from Ben Creelan, MD lab showing subclonal neoantigen loss in tumours progressing on TIL therapy highlighting importance of targeting clonal neoantigens - watch this space for Darwin2 trial reported ESMO - Eur. Oncology by Crispin Hiley Nicholas McGranahan

Excited to help show biology of TIL cell therapy resistance in lung cancer in real world samples: >Missing neoantigens at progression >Failure of persistence of antigen-specific clones >HLA LOH Ben Creelan, MD Chao Wang Nature Cancer nature.com/articles/s4301…

Importance of targeting clonal neoantigens and circumventing dysfunctional states in TIL therapy! 10 years on Andrew Furness Nicholas McGranahan Charles Swanton Quezada Lab Sergio Quezada

Our real world study on the dynamic co-evolution between multivalent TIL and heterogeneous TME: >Missing neoAg at progression >Failure of persistence of antigen-specific clones >HLA LOH Ben Creelan, MD Jose Conejo-Garcia Nature Cancer Moffitt Cancer Center nature.com/articles/s4301…

x.com/i/article/1920…

What’s next for #NSCLC care? Join me, Heather Wakelee, @TinaCasconeMD & Dr. Julie Brahmer at PeerView/LUNGevity Foundation’s #ASCO25 symposium! 🚩Hyatt Regency Chicago 🕣May 30 | 6:30 PM CDT – Dinner 7–8:30 PM CDT / 8 –9:30 PM EDT – Symposium 🔗bit.ly/2025NSCLCT #OncologyEducation

#ASCO2025 abstracts release 5 pm EST today. Made a list of Top30 in solid cell therapy to watch for tonight. 🚀

Westlake Therapeutics posting DCR 85.7% (6/7) and ORR 57.1% (4/7) in highest dose engineered RBC infusions for PD1 refractory solid tumors 🫢 14 total pts, 5 PR,1 CR. 🚩Hall D2 Oral 🕤Sat 5/31; 5 – 5:12 PM CDT My discussion talk to follow! meetings.asco.org/2025-asco-annu… #ASCO25

🚶‍♂️ Heading to PeerView’s #NSCLC and #CRC sessions today at 6:30 PM during #ASCO25? Here’s how to get to the Regency Ballroom AB & CD (Ballroom Level, West Tower) at the Hyatt Regency Chicago. Follow along for an evening of expert insights! 🔗 bit.ly/Onc25T Heather Wakelee

Conjugating PD1 antibody to RBCs yields responses in refractory solid tumors - is this delivery better than conventional antibodies? Kudos to Dr Nie from Westlake University for this #asco25 oral abstract & Meredith Pelster Dr Sarah Nikiforow for chairing

Groundbreaking data from Dr Martin Wermke showing ORR 56%, DOR 12.1 months in PD-1 R/R melanomas in a phase I trial at KOUAKOU Eager to further explore this strategy in other tumor types that express PRAME! Jason Luke, MD, FACP Harpreet Singh

Congrats to my colleague Lilit Karapetyan presenting 49% ORR for TIL in real-world setting! Response rates higher if 3L or earlier patients -ORR 61% (14/23). 🎉 This is a call for earlier referrals in academics. Moffitt Cancer Center Allison Betof Warner, MD, PhD 👉ir.iovance.com/news-releases/…